查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1953477

代謝體學市場－全球產業規模、佔有率、趨勢、機會及預測（依產品、適應症、應用、地區及競爭格局分類，2021-2031年）

Metabolomics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product, By Indication, By Application, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 181 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球代謝體學市場預計將從 2025 年的 34.8 億美元成長到 2031 年的 58.4 億美元，複合年成長率為 9.01%。

代謝體學是對小分子化合物（或稱為「代謝物」）進行全面的科學分析，這些代謝物是存在於生物樣本（例如體液、組織和細胞）中的代謝中間體和產物。該市場的成長主要受個人化醫療需求的不斷成長以及迫切需要尋找新的生物標記來管理日益增多的慢性疾病的驅動。此外，該領域也受益於藥物研發領域的大量投資，這些投資利用代謝譜分析來加速藥物測試和發現。根據代謝體學學會2024年發布的公告，該組織擁有來自40多個國家的1000多名會員，這表明該行業擁有不斷擴大的合作網路和全球專業知識支持。

市場概覽
預測期 2027-2031
市場規模：2025年 34.8億美元
市場規模：2031年 58.4億美元
複合年成長率：2026-2031年 9.01%
成長最快的細分市場 癌症
最大的市場 北美洲

儘管發展勢頭強勁，但該市場仍面臨諸多挑戰：高維度資料分析的複雜性以及缺乏通用標準化的資料庫。先進儀器產生的大量資訊需要複雜的生物資訊工具和高技能專家進行解讀，造成技術瓶頸。這項挑戰可能會減緩研究成果轉化為常規臨床應用的進程，並可能阻礙市場的進一步擴張。

市場促進因素

製藥和生物製藥行業研發投入的不斷成長是全球代謝生物分析市場的主要驅動力。各公司正逐步將代謝譜分析納入先導化合物發現流程，以改善先導化合物最佳化和毒性評估，而這筆巨額資金投入也推動了高解析度質譜和核磁共振等必要技術的應用。這項投資規模龐大；例如，羅氏在2024年2月發布的2023年度報告中揭露，其研發總支出高達132億瑞士法郎，凸顯了生命科學研究領域巨額資金的湧入。此外，布魯克在2024年宣布，2023會計年度的銷售額將達到29.6億美元，顯示市場對支持代謝生物分析的科學工具的需求持續強勁。

慢性疾病的日益增多，既加速了生物標記發現的需求，也推動了市場成長。代謝體學提供了一種獨特的觀點，可以從分子水平檢測表現型變化，因此對於識別癌症等疾病的早期診斷標記至關重要。隨著疾病負擔的加重，開發精準診斷方法的壓力也與日俱增。根據美國癌症協會於2024年1月發布的《2024年癌症事實與數據》，預計僅在美國就將新增2,001,140例癌症病例，這凸顯了臨床上迫切需要可靠的代謝生物標記來改善患者分層和治療效果。

市場挑戰

全球代謝生物化學市場成長的主要障礙在於高維度資料分析的複雜性以及缺乏通用標準化的資料庫。儘管先進的分析儀器能夠產生龐大而複雜的資料集，但由於缺乏一致的參考資料庫，代謝物的準確鑑定效率低下且結果易受差異影響。這種標準化的缺失導致研究工作分散，難以比較不同實驗室和研究的數據。因此，將代謝發現轉化為可靠且可重複的臨床生物標記的過程被顯著延緩，使得製藥公司和臨床醫生在將這些技術應用於常規診斷時猶豫不決。

此外，由於缺乏能夠運用先進生物資訊學工具的人才，該領域面臨嚴重的瓶頸。分析技術的快速發展速度超過了訓練有素的專業人員的供給速度，而這些專業人員需要能夠解讀由此產生的生物數據。根據 OBN 2024 年的一項調查，超過 36% 的生命科學雇主表示，他們缺乏充分利用新興數據技術所需的技能。這種嚴重的人才短缺直接限制了該行業充分利用代謝組學分析的效用，減緩了代謝組學融入主流醫療保健的進程，並阻礙了其更廣泛的市場擴張。

市場趨勢

人工智慧 (AI) 和機器學習在數據分析領域的快速融合，正從根本上重塑全球代謝體學市場，其關鍵瓶頸在於高維度數據的複雜性。隨著代謝體學資料集規模日益龐大、結構日益複雜，傳統的人工解讀方式已無法滿足需求，因此亟需藉助人工智慧驅動的演算法來實現代謝物自動識別、批次效應歸一化以及細微生物學模式的發現。這種技術變革並非僅僅停留在理論層面，它正在積極推動生命科學領域的營運投資。根據英偉達 (NVIDIA) 於 2025 年 7 月發布的報告《醫療保健和生命科學領域的人工智慧現狀：2025 年趨勢》，78% 的受訪行業人士計劃在 2025 年增加人工智慧預算，這反映出企業正明顯轉向採用計算解決方案來提高體學研究的速度和準確性。

同時，空間代謝成像和質譜技術的出現正在改變市場格局，它能夠可視化活體組織環境中的代謝物分佈。與將樣本均質化的總體分析不同，空間代謝成像保留了分子的組織學定位，從而為腫瘤微環境和細胞異質性提供了前所未有的洞察。主要儀器製造商正透過收購專業的太空生物學平台並將其整合到現有的質譜產品組合中，來滿足這一市場需求並擴大收入。根據布魯克公司於2025年2月發布的2024年度報告，該公司在2024會計年度實現了超過33億美元的公司營收。這項財務里程碑主要歸功於其太空生物學部門的策略擴張以及公司新型高通量成像技術的應用。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球代謝體學市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依產品分類（代謝體學設備、代謝體學物資訊學工具及服務）
    • 按適應症（癌症、心血管疾病、神經系統疾病、先天性代謝疾病等）
    • 依應用領域（生物標記/藥物發現、毒理學、營養基因體學、個人化醫療等）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美代謝體學市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

7. 歐洲代謝體學市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

8. 亞太地區代謝體學市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

9. 中東和非洲代謝體學市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲代謝體學市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進要素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 最新進展

第13章 全球代謝體學市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的可能性
  • 供應商電力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Metabolon, Inc.
  • Agilent Technologies, Inc.
  • Bruker Corporation
  • Human Metabolome Technologies America, Inc.
  • Thermo Fisher Scientific Inc.
  • Shimadzu Corporation
  • Danaher Corporation
  • Waters Corporation
  • Metware Biotechnology Inc.
  • Afekta Technologies Ltd.

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 24400

The Global Metabolomics Market is anticipated to expand from USD 3.48 Billion in 2025 to USD 5.84 Billion by 2031, registering a CAGR of 9.01%. Metabolomics is defined as the exhaustive scientific examination of metabolites, which are the small-molecule intermediates and byproducts of metabolism present in biological samples like biofluids, tissues, and cells. The growth of this market is primarily fueled by the increasing demand for personalized medicine and the urgent necessity to identify novel biomarkers for managing the growing prevalence of chronic diseases. Furthermore, the sector benefits from significant investments in pharmaceutical research and development, which employ metabolic profiling to expedite toxicology testing and drug discovery. As noted by the Metabolomics Society in 2024, the organization included more than 1,000 members from over 40 countries, illustrating the widening collaborative network and global expertise supporting this industry.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 3.48 Billion
Market Size 2031USD 5.84 Billion
CAGR 2026-20319.01%
Fastest Growing SegmentCancer
Largest MarketNorth America

Despite these driving forces, the market encounters a major obstacle regarding the intricacy of high-dimensional data analysis and the absence of universally standardized databases. The immense volume of information produced by advanced instrumentation necessitates sophisticated bioinformatics tools and highly skilled professionals for interpretation, resulting in a technical bottleneck. This challenge threatens to delay the translation of research findings into routine clinical applications and could hinder broader market expansion.

Market Driver

Increasing research and development expenditure within the pharmaceutical and biopharmaceutical sectors serves as a major catalyst for the Global Metabolomics Market. Companies are progressively incorporating metabolic profiling into their drug development processes to improve lead optimization and toxicity assessment, a financial commitment that enables the deployment of essential high-resolution mass spectrometry and nuclear magnetic resonance technologies. The scale of this investment is significant; for example, Roche reported a total R&D spend of CHF 13.2 billion in its 2023 Annual Report published in February 2024, emphasizing the massive capital entering life sciences research. Additionally, Bruker Corporation reported fiscal year 2023 revenues of $2.96 billion in 2024, reflecting persistent industrial demand for the scientific tools that underpin metabolomic analysis.

The growing prevalence of chronic diseases is simultaneously accelerating the need for biomarker discovery, thereby propelling market growth. Metabolomics provides a distinct vantage point by detecting phenotypic changes at the molecular level, making it essential for identifying early diagnostic markers for conditions such as cancer. As the disease burden increases, the pressure to develop precision diagnostics intensifies. According to the American Cancer Society's 'Cancer Facts & Figures 2024' released in January 2024, it is projected that there will be 2,001,140 new cancer cases in the United States alone, highlighting the urgent clinical need for robust metabolic biomarkers to improve patient stratification and treatment outcomes.

Market Challenge

The primary hurdle restricting the growth of the Global Metabolomics Market is the complexity associated with high-dimensional data analysis combined with the lack of universally standardized databases. As advanced instrumentation produces massive and intricate datasets, the absence of consistent reference libraries renders the accurate identification of metabolites inefficient and prone to variability. This standardization deficit fragments research efforts, making data difficult to compare across different laboratories or studies. Consequently, the translation of metabolic discoveries into reliable, reproducible clinical biomarkers is significantly stalled, causing pharmaceutical companies and clinicians to hesitate in adopting these technologies for routine diagnostic applications.

Moreover, this sector faces a critical bottleneck due to a shortage of personnel capable of navigating sophisticated bioinformatics tools. The rapid evolution of analytical technologies has outpaced the supply of experts trained to interpret the resulting biological data. According to OBN in 2024, over 36% of life sciences employers reported they did not have access to the right skills to fully leverage emerging data technologies. This acute talent gap directly restricts the industry's capacity to maximize the utility of metabolic profiling, thereby slowing the integration of metabolomics into mainstream healthcare and limiting broader market expansion.

Market Trends

The rapid integration of Artificial Intelligence and Machine Learning for Data Analysis is fundamentally reshaping the Global Metabolomics Market by addressing the critical bottleneck of high-dimensional data complexity. As metabolomic datasets become increasingly voluminous and intricate, traditional manual interpretation is proving insufficient, necessitating AI-driven algorithms to automate metabolite identification, normalize batch effects, and uncover subtle biological patterns. This technological shift is not merely theoretical but is actively driving operational investment across the life sciences sector. According to NVIDIA's 'State of AI in Healthcare and Life Sciences: 2025 Trends' report from July 2025, 78% of industry respondents indicated that their artificial intelligence budgets would grow in 2025, reflecting a decisive pivot toward computational solutions to enhance the speed and accuracy of omics research.

Simultaneously, the emergence of Spatial Metabolomics and Mass Spectrometry Imaging is transforming the market by enabling the visualization of metabolite distribution within the native tissue context. Unlike bulk analysis, which homogenizes samples, spatial metabolomics preserves the histological localization of molecules, offering unprecedented insights into tumor microenvironments and cellular heterogeneity. Leading instrument manufacturers are capitalizing on this demand by acquiring specialized spatial biology platforms and integrating them into their existing mass spectrometry portfolios to drive revenue. According to Bruker Corporation's 'Annual Report 2024' released in February 2025, the company delivered fiscal year 2024 revenues of over $3.3 billion, a financial milestone attributed significantly to the strategic expansion of its spatial biology division and the adoption of its novel high-plex imaging technologies.

Key Market Players

  • Metabolon, Inc.
  • Agilent Technologies, Inc.
  • Bruker Corporation
  • Human Metabolome Technologies America, Inc.
  • Thermo Fisher Scientific Inc.
  • Shimadzu Corporation
  • Danaher Corporation
  • Waters Corporation
  • Metware Biotechnology Inc.
  • Afekta Technologies Ltd.

Report Scope

In this report, the Global Metabolomics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Metabolomics Market, By Product

  • Metabolomics Instruments
  • Metabolomics Bioinformatics Tools & Services

Metabolomics Market, By Indication

  • Cancer
  • Cardiovascular Disorders
  • Neurological Disorders
  • Inborn Errors of Metabolism
  • Others

Metabolomics Market, By Application

  • Biomarker and Drug Discovery
  • Toxicology
  • Nutrigenomics
  • Personalized Medicine
  • Others

Metabolomics Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Metabolomics Market.

Available Customizations:

Global Metabolomics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Metabolomics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product (Metabolomics Instruments, Metabolomics Bioinformatics Tools & Services)
    • 5.2.2. By Indication (Cancer, Cardiovascular Disorders, Neurological Disorders, Inborn Errors of Metabolism, Others)
    • 5.2.3. By Application (Biomarker and Drug Discovery, Toxicology, Nutrigenomics, Personalized Medicine, Others)
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America Metabolomics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product
    • 6.2.2. By Indication
    • 6.2.3. By Application
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Metabolomics Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product
        • 6.3.1.2.2. By Indication
        • 6.3.1.2.3. By Application
    • 6.3.2. Canada Metabolomics Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product
        • 6.3.2.2.2. By Indication
        • 6.3.2.2.3. By Application
    • 6.3.3. Mexico Metabolomics Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product
        • 6.3.3.2.2. By Indication
        • 6.3.3.2.3. By Application

7. Europe Metabolomics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product
    • 7.2.2. By Indication
    • 7.2.3. By Application
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Metabolomics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product
        • 7.3.1.2.2. By Indication
        • 7.3.1.2.3. By Application
    • 7.3.2. France Metabolomics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product
        • 7.3.2.2.2. By Indication
        • 7.3.2.2.3. By Application
    • 7.3.3. United Kingdom Metabolomics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product
        • 7.3.3.2.2. By Indication
        • 7.3.3.2.3. By Application
    • 7.3.4. Italy Metabolomics Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product
        • 7.3.4.2.2. By Indication
        • 7.3.4.2.3. By Application
    • 7.3.5. Spain Metabolomics Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product
        • 7.3.5.2.2. By Indication
        • 7.3.5.2.3. By Application

8. Asia Pacific Metabolomics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product
    • 8.2.2. By Indication
    • 8.2.3. By Application
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Metabolomics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product
        • 8.3.1.2.2. By Indication
        • 8.3.1.2.3. By Application
    • 8.3.2. India Metabolomics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product
        • 8.3.2.2.2. By Indication
        • 8.3.2.2.3. By Application
    • 8.3.3. Japan Metabolomics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product
        • 8.3.3.2.2. By Indication
        • 8.3.3.2.3. By Application
    • 8.3.4. South Korea Metabolomics Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product
        • 8.3.4.2.2. By Indication
        • 8.3.4.2.3. By Application
    • 8.3.5. Australia Metabolomics Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product
        • 8.3.5.2.2. By Indication
        • 8.3.5.2.3. By Application

9. Middle East & Africa Metabolomics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product
    • 9.2.2. By Indication
    • 9.2.3. By Application
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Metabolomics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product
        • 9.3.1.2.2. By Indication
        • 9.3.1.2.3. By Application
    • 9.3.2. UAE Metabolomics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product
        • 9.3.2.2.2. By Indication
        • 9.3.2.2.3. By Application
    • 9.3.3. South Africa Metabolomics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product
        • 9.3.3.2.2. By Indication
        • 9.3.3.2.3. By Application

10. South America Metabolomics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product
    • 10.2.2. By Indication
    • 10.2.3. By Application
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Metabolomics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product
        • 10.3.1.2.2. By Indication
        • 10.3.1.2.3. By Application
    • 10.3.2. Colombia Metabolomics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product
        • 10.3.2.2.2. By Indication
        • 10.3.2.2.3. By Application
    • 10.3.3. Argentina Metabolomics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product
        • 10.3.3.2.2. By Indication
        • 10.3.3.2.3. By Application

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Metabolomics Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Metabolon, Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Agilent Technologies, Inc.
  • 15.3. Bruker Corporation
  • 15.4. Human Metabolome Technologies America, Inc.
  • 15.5. Thermo Fisher Scientific Inc.
  • 15.6. Shimadzu Corporation
  • 15.7. Danaher Corporation
  • 15.8. Waters Corporation
  • 15.9. Metware Biotechnology Inc.
  • 15.10. Afekta Technologies Ltd.

16. Strategic Recommendations

17. About Us & Disclaimer